125683 📌 🚀

High concentration (20%) allows for lower infusion volumes and faster delivery. Generally well-tolerated at rates up to 35 mL/hour/site. Primary Risks

: While the Statistical Review noted some limitations due to small sample sizes in higher-rate groups, they concluded there were no major statistical issues that would prevent the labeling changes. 125683

: This increase allows for significantly shorter infusion times, which is a major factor in treatment adherence and quality of life for patients requiring long-term immune globulin replacement therapy. High concentration (20%) allows for lower infusion volumes

: Pharmacokinetic (PK) data supported the safety of these changes, confirming that the drug's effectiveness in maintaining protective IgG levels remains consistent even with faster administration. Summary of Benefits vs. Risks Clinical Observation Primary Indication Treatment of Primary Immunodeficiency (PI). Key Advantage : This increase allows for significantly shorter infusion